ERCC2多态性与肺癌铂类化疗敏感性的关系

Correlation of excision repair cross-complementing group 2 polymorphisms and response to platinum-based chemotherapy in advanced non-small cell lung cancer

目的研究切除修复交叉互补基因2(ERCC2)多态性与晚期非小细胞肺癌对铂类药物化疗敏感性的关系。方法应用基因芯片方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC2Asp312Asn和Lys751Gln基因型,比较不同基因型与化疗疗效的关系。结果 89例患者化疗总有效率为29.2%。ERCC2Asp312Asn和Lys751Gln基因型在化疗有效组和无效组之间的分布无差异(P>0.05)。结论 ERCC2Asp312Asn和Lys751Gln单核苷酸多态性与晚期非小细胞肺癌对铂类药物化疗敏感性无关。

[Objective] To investigate the relationship between ERCC2 single nueleotide polymorphisms and sensitivity to platinum-based chemotherapy among patients with advanced non small cell lung cancer. [Methods] We used gene ehip analysis to determine the single nueleotide polymorphisms （SNPs） of excision repair eross-complemenfing group 2 （ERCC2） in DNA from peripheral lymphocytes. Totally 89 patients with NSCLC were treated with platinum -based chemotherapy, and clinical response was evaluated after 2 cycles. The association between ERCC2 gene polymorphisms and chemo-sensitivity were analyzed. [Restdts] The overall response rate was 29.2%. Chemotherapy response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC2 gene （P 〉0.05）. [Conclusions] ERCC2 Asp312Asn and Lys751Gln SNP may be not associated with sensitivity to platinum-based chemotherapy in advanced NSCLC patients.